Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00047814 · ClinicalTrials.gov registry record · Phase 2

Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection

A Phase 2 study of Hepatitis C, sponsored by Astellas Pharma.

Completed
Registry status
Phase 2
Development phase
48
Enrollment target
9
Study locations

NCT00047814 is a Phase 2 study of Hepatitis C that has completed, run by Astellas Pharma. The registered enrollment target is 48 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (97% lower). The trial reports 9 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00047814, a Phase 2 study of Hepatitis C, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of 4 weeks therapy with FK788 in subjects with chronic hepatitis C virus (HCV) infection. Also, to assess the effect of FK788 on serum ALT concentration and hepatitis C viral level during therapy and for four weeks following therapy.

Conditions Studied

Hepatitis C

Interventions

  • DRUG FK788

Study Locations (9)

North Carolina

  • Carolinas Center for Liver Disease - Charlotte
  • Duke University - Durham

California

  • Liver Center Huntington Memorial Hospital - Pasadena

Colorado

  • Rocky Mount Gastroenterology - Lakewood

Florida

  • University of Florida and Shands Hospital - Gainsville

Massachusetts

  • Liver Center BIDMC - Harvard - Boston

Missouri

  • Gastroenterology and Hepatology - Kansas City

Pennsylvania

  • Thomas Jefferson University, Gastroenterology and Hepatology - Philadelphia

Washington

  • Northwest Medical Specialties, PLLC Infections Limited, P.S. - Tacoma

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2002-10
Est. Completion 2006-03
Phase Phase 2

Sponsor

Astellas Pharma

165 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00047814

The ClinicalTrials.gov registry entry for NCT00047814 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (97% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which FK788 is the first listed.

NCT00047814 reports 9 study locations spanning 8 distinct geographic areas - top geographies include North Carolina, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT00047814 about?

NCT00047814 is a clinical study titled "Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection". The purpose of this study is to assess the safety, tolerability and pharmacokinetics of 4 weeks therapy with FK788 in subjects with chronic hepatitis C virus (HCV) infection. Also, to assess the effect of FK788 on serum ALT concentration and hepatitis C viral level during therapy and for four weeks ...

What is the current status of trial NCT00047814?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2002-10. Estimated completion is 2006-03.

What conditions does trial NCT00047814 study?

This clinical trial studies the following conditions: Hepatitis C.

What interventions are being tested in trial NCT00047814?

The interventions under investigation include: FK788 (DRUG).

Who is sponsoring clinical trial NCT00047814?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00047814 being conducted?

This trial has 9 study locations across California, Colorado, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis C

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.